💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Binimetinib

CHEMBL3187723 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
441.2 g/mol
LogP
3.1
Phase
4

A targeted therapy that inhibits the MEK enzyme in the MAPK signaling pathway, which is often abnormally activated in certain cancers. It is used in combination with another targeted agent to treat melanoma and other tumors with specific genetic mutations. Side effects can include rash, visual disturbances, and elevated liver enzymes.

आणविक भार

441.2000 g/mol

LogP

3.10

TPSA

88.40 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अग्नाशय कैंसर ओवेरियन कैंसर कोलोरेक्टल कैंसर थायरॉइड कैंसर नॉन-स्मॉल सेल लंग कैंसर प्रोस्टेट कैंसर मूत्राशय कैंसर मेलानोमा लिम्फोमा ल्यूकेमिया स्तन कैंसर

क्रिया का तंत्र

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21

                

                

                
                

                    
InChI

                    
InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H15BrF2N4O3

                    

                    
                    

                        
HBD / HBA

                        
3 / 7

                    

                    
                    

                        
घूर्णनीय बंधन

                        
6

                    

                    
                    
                    

                        
भारी परमाणु

                        
27

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
A targeted therapy that inhibits the MEK enzyme in the MAPK signaling pathway, which is often abnormally activated in certain cancers. It is used in combination with another targeted agent to treat melanoma and other tumors with specific genetic mutations. Side effects can include rash, visual disturbances, and elevated liver enzymes.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Binimetinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3187723.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10288191.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.